Quality -of-life scores ( Piper Fatigue Scale MD 0.73 , 95 % CI 0.29 to 1.18 ; I2 = 0 % ; studies = 3 ) and peak oxygen consumption ( MD 2.77 mL/kg/min , 95 % CI -0.89 to 6.43 ; I2 = 36 % ; 2 studies , 32 participants ) were associated with very low- quality evidence , and we remain uncertain about the role of intravenous iron for these metrics .
Current evidence is insufficient to show benefit of intravenous iron preparations for the treatment of non-anaemic iron deficiency across a variety of patient population s , beyond stating that it may result in a small , clinical ly insignificant increase in haemoglobin concentration .
BACKGROUND Iron deficiency is one of the most common nutritional deficiencies , and has a number of physiological manifestations .
Early , or non-anaemic iron deficiency can result in fatigue and diminished exercise capacity .
Oral iron preparations have a high incidence of intolerable side effects , and are ineffective in certain forms of iron deficiency .
Consequently , intravenous iron preparations are increasingly used in the treatment of non-anaemic iron deficiency .
The newer , more stable iron preparations in particular purport to have a lower incidence of side effects , and are now used across a range of different patient population s. OBJECTIVES To assess the effects of intravenous iron therapy in the treatment of adults with non-anaemic iron deficiency .
The Important Role for Intravenous Iron in Perioperative Patient Blood Management in Major Abdominal Surgery
Objective : To determine if preoperative intravenous ( IV ) iron improves outcomes in abdominal surgery patients . Summary Background Data : Preoperative iron deficiency anemia ( IDA ) occurs frequently ; however if left untreated , increases the risk of blood transfusion allogeneic blood transfusion ( ABT ) . Limited evidence supports IDA treatment with preoperative IV iron . This r and omized controlled trial aim ed to determine whether perioperative IV iron reduced the need for ABT . Methods : Between August 2011 and November 2014 , 72 patients with IDA were assigned to receive either IV iron or usual care . The primary endpoint was incidence of ABT . Secondary endpoints were various hemoglobin ( Hb ) levels , change in Hb between time points , length of stay , iron status , morbidity , mortality , and quality of life 4 weeks postsurgery . Results : A 60 % reduction in ABT was observed in the IV iron group compared with the usual care group ( 31.25 % vs 12.5 % ) . Hb values , although similar at r and omization , improved by 0.8 g/dL with IV iron compared with 0.1 g/dL with usual care ( P = 0.01 ) by the day of admission . The IV iron group had higher Hb 4 weeks after discharge compared with the usual care group ( 1.9 vs 0.9 g/dL , P = 0.01 ) , and a shorter length of stay ( 7.0 vs 9.7 d , P = 0.026 ) . There was no difference in discharge Hb levels , morbidity , mortality , or quality of life . Conclusions : Administration of perioperative IV iron reduces the need for blood transfusion , and is associated with a shorter hospital stay , enhanced restoration of iron stores , and a higher mean Hb concentration 4 weeks after surgery
Quality -of-life scores ( Piper Fatigue Scale MD 0.73 , 95 % CI 0.29 to 1.18 ; I2 = 0 % ; studies = 3 ) and peak oxygen consumption ( MD 2.77 mL/kg/min , 95 % CI -0.89 to 6.43 ; I2 = 36 % ; 2 studies , 32 participants ) were associated with very low- quality evidence , and we remain uncertain about the role of intravenous iron for these metrics .
Current evidence is insufficient to show benefit of intravenous iron preparations for the treatment of non-anaemic iron deficiency across a variety of patient population s , beyond stating that it may result in a small , clinical ly insignificant increase in haemoglobin concentration .
BACKGROUND Iron deficiency is one of the most common nutritional deficiencies , and has a number of physiological manifestations .
Early , or non-anaemic iron deficiency can result in fatigue and diminished exercise capacity .
Oral iron preparations have a high incidence of intolerable side effects , and are ineffective in certain forms of iron deficiency .
Consequently , intravenous iron preparations are increasingly used in the treatment of non-anaemic iron deficiency .
The newer , more stable iron preparations in particular purport to have a lower incidence of side effects , and are now used across a range of different patient population s. OBJECTIVES To assess the effects of intravenous iron therapy in the treatment of adults with non-anaemic iron deficiency .